JCR Pharmaceuticals Co Ltd

JCR Pharmaceuticals has a market capitalization of ¥61.73 billion and a price-to-book ratio of 1.31, indicating a moderate premium over its book value. The company's liquidity position is characterized as medium risk, with negative free cash flow of ¥13.72 billion and operating cash flow of ¥-5.49 billion, suggesting cash outflows from operations. The current ratio of 1.16 indicates that the company has just enough current assets to cover its current liabilities, but not with a significant buffer. Profitability metrics show a challenging financial position, with a return on equity (ROE) of -10.12% and a return on assets (ROA) of -4.54%, both significantly below the industry median for pharmaceutical firms. The company reported a net loss of ¥4.76 billion and an operating loss of ¥5.78 billion, reflecting a difficult operating environment. Gross profit of ¥21.74 billion is a positive sign, but it is insufficient to offset the operating and net losses. Geographically, JCR Pharmaceuticals is heavily concentrated in the Japanese market, with no disclosed international revenue segments. This concentration increases exposure to domestic regulatory and economic conditions. The company's revenue of ¥33.07 billion is derived from a limited number of products, with no disclosed segment breakdown, which may indicate a lack of diversification. Looking ahead, the company is expected to face continued financial pressure, with no disclosed revenue growth in the current fiscal year. The operating loss and net loss are likely to persist unless there is a significant turnaround in product performance or cost management. The company's capital expenditure of ¥-9.89 billion suggests ongoing investment in infrastructure or R&D, but the negative free cash flow indicates that these investments are not yet generating positive returns. The risk assessment highlights liquidity concerns, with a debt-to-equity ratio of 0.81 and a negative net cash position after subtracting total debt. The company's liquidity risk is moderate, but the negative operating and free cash flows suggest a need for careful monitoring of cash reserves. The dilution risk is currently low, with no significant dilution events reported in the latest filings. Recent analyst estimates suggest a mixed outlook, with a mean price target of ¥711.43 and a median of ¥690.00. The mean recommendation of 2.71 indicates a cautious stance, with six "hold" ratings and only one "strong buy". No recent filings or transcripts have been disclosed that would indicate a material change in the company's strategic direction or financial outlook.